关于SEBMC  
SEBMC章程  
SEBMC活动  
执行理事会
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nick Zhang
China General Manager and Corporate Sr. VP of Frontage Lab, Inc.

 

Nick Zhang has over 18 years of industry drug research and development experience. He is currently China General Manager and Corporate Sr. VP of Frontage Lab, Inc.  He oversees all business units (CMC, Clinical development and Bioanalytical service) for Frontage China.  He is responsible for China’s operation, business and growth.  Nick also serves on the SFDA Working Committee for Bayhelix as well as serves as reviewer for China Thousand Talents Program organized by the China Bureau of Human Resources, Department of Organization, and Ministry of S&T.
Prior to Frontage, Nick was a director and China CPP/TRD head for Novartis China R&D center, responsible for leading teams of supporting local and global projects from Lead optimization to drug product development. He returned to China in 2007 as one of the executive founding members of the center, and contributed greatly to the build-up and strategic planning of the Novartis site. In addition, He built up his organization from scratch to now a fully functional division. Prior to Novartis, Nick was at OSI Pharmaceuticals in US where he was a director of pharmaceutical science division and a department head. After OSI acquired EyeTech in 2006, Nick was part of the integration team for setting up CMC business model and strategies.
Nick started his drug R&D career in US at Pfizer global R&D Center after his Ph.D from University of Cincinnati. During his ten years at Pfizer, Nick led both Early and Full Development teams at Pharmaceutical Science division, filed 6 INDs/IMPD for solid and liquid dosage forms and 1 NDA/MAA (Exubera) for inhaled delivery technology. Nick represented Pfizer serving on the PRQI (Product Quality and Research Institute) working committee, a joint organization from FDA, pharmaceutical industry and academia for regulatory policy based on science. Nick also served in Pfizer Global Leachable/Extractable Taskforce and ARD Regulatory Response Team.
Nick gained his initial drug research experience at Chinese Academy of Sciences in 1986 where he worked and studied for 4 years, and subsequently in 1990 at University of Cincinnati from where he obtained his Ph.D degree in Chemistry by studying metal-containing medicines and their metabolism mechanism.